EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis



Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis



Antimicrobial Agents and ChemoTherapy 49(12): 4867-4875



Central nervous system (CNS) aspergillosis is a severe disease that responds poorly to current therapies. The current studies examined the efficacies of several antifungal agents alone or in combination with a murine model of CNS aspergillosis. Immunosuppressed mice were infected intracerebrally with Aspergillus fumigatus and treated with an amphotericin B preparation, an echinocandin, or voriconazole (VCZ) given alone or in combination. Monotherapy studies showed that micafungin (MICA), caspofungin (CAS), VCZ, conventional amphotericin B (AMB), Abelcet (ABLC) (a lipid-carried AMB formulation; Enzon Pharmaceuticals, Inc.), and AmBisome (AmBi) (liposomal AMB; Gilead Sciences, Inc.) were efficacious. However, doses of AmBi above 15 mg/kg of body weight showed reduced efficacy. Neither MICA nor CAS showed dose responsiveness at the doses tested (1, 5, or 10 mg/kg). Only the 40-mg/kg dose of VCZ was effective. AmBi and ABLC showed dose responsiveness, with 10-mg/kg doses causing a significant reduction in fungal burden; they had equivalent activities at the 10-mg/kg dose. Suboptimal dosages of AmBi in combination with MICA, CAS, or VCZ were effective in prolonging survival. However, significantly enhanced activity was demonstrated only with AmBi and VCZ in combination. AmBi in combination with MICA or CAS showed a trend toward enhanced activity, but the combination was not significantly superior to monotherapy. The use of AmBi with CAS or VCZ at optimal doses did not improve efficacy. Cure was not attained with any dosage combinations. These results indicate that AmBi in combination with VCZ may be superior for treatment of CNS aspergillosis; combinations of AmBi and MICA or CAS were not antagonistic and may have a slight benefit.

(PDF emailed within 0-6 h: $19.90)

Accession: 004408751

Download citation: RISBibTeXText

PMID: 16304147

DOI: 10.1128/AAC.49.12.4867-4875.2005



Related references

A retrospective clinical comparison between antifungal treatment with liposomal amphotericin B (AmBisome) and conventional amphotericin B in transplant recipients : Retrospektiver klinischer Vergleich der antimykotischen Therapie mit liposomalem Amphotericin B (AmBisome) und konventionellem Amphotericin B bei Transplantationspatienten. Mycoses 35(9-10): 215-220, 1992

Efficacy of SPK-843, a novel polyene antifungal, in comparison with amphotericin B, liposomal amphotericin B, and micafungin against murine pulmonary aspergillosis. Antimicrobial Agents and ChemoTherapy 52(5): 1868-1870, 2008

Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin. Journal of Antimicrobial ChemoTherapy 52(4): 656-662, 2003

Comparative efficacies of four amphotericin B formulations--Fungizone, amphotec (Amphocil), AmBisome, and Abelcet--against systemic murine aspergillosis. Antimicrobial Agents and ChemoTherapy 48(3): 1047-1050, 2004

In vitro antifungal activity of voriconazole in two-drug combination with micafungin, caspofungin and amphotericin B. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 41: 364, 2001

Comparative study on the efficacy of liposomal amphotericin B and voriconazole in a murine pulmonary aspergillosis model. ChemoTherapy 55(2): 105-113, 2009

Efficacies of amphotericin B-desoxycholate (Fungizone), liposomal amphotericin B (AmBisome) and fluconazole in the treatment of systemic candidosis in immunocompetent and leucopenic mice. Journal of Antimicrobial Chemotherapy 32(5): 723-739, 1993

Efficacy of combination antifungal therapy with intraperitoneally administered micafungin and aerosolized liposomal amphotericin B against murine invasive pulmonary aspergillosis. Antimicrobial Agents and ChemoTherapy 53(8): 3508-3510, 2009

Efficacy of amphotericin B or amphotericin B-intralipid in combination with caspofungin against experimental aspergillosis. Journal of Infection 53(2): 131-139, 2005

Therapeutic efficacy of amphotericin b lipid complex , amphotericin b colloidal dispersion , liposomal amphotericin b , and conventional amphotericin b in murine coccicioidomycosis. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 42: 372, 2002

Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin. Pediatric Infectious Disease Journal 26(4): 364-366, 2007

Successful treatment of angioinvasive aspergillosis during prolonged neutropenia with liposomal amphotericin, voriconazole, and caspofungin. Infectious Diseases in Clinical Practice 11(6): 355-358, 2002

Prophylactic efficacy of aerosolized liposomal (AmBisome) and non-liposomal (Fungizone) amphotericin B in murine pulmonary aspergillosis. Journal of Antimicrobial ChemoTherapy 34(6): 1001-1013, 1994

Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrobial Agents and ChemoTherapy 46(3): 834-840, 2002

Liposomal amphotericin B (AmBisome) reduces dissemination of infection ad compared with amphotericin B deoxycholate (Fungizone) in a rat model of pulmonary aspergillosis. Journal of Antimicrobial ChemoTherapy 38(2): 215-225, 1996